Truist Financial
XLRN

Truist Financial’s Acceleron Pharma XLRN Stock Holding History

Truist Financial’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,749
Closed -$644K – 2849
2021
Q1 		$644K Sell
4,749
-140
-3% -$18.1K ﹤0.01% 1837
2020
Q4 		$626K Sell
4,889
-81
-2% -$9.5K ﹤0.01% 1747
2020
Q3 		$559K Sell
4,970
-491
-9% -$48.9K ﹤0.01% 1665
2020
Q2 		$520K Buy
5,461
+2,079
+61% +$200K ﹤0.01% 1601
2020
Q1 		$303K Sell
3,382
-823
-20% -$64K ﹤0.01% 1856
2019
Q4 		$223K Buy
+4,205
New +$192K ﹤0.01% 2310

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Truist Financial's XLRN Position: Q2 2021 in Review

Truist Financial sold out of Acceleron Pharma (XLRN) in Q2 2021, closing a stake of 4,749 shares — an estimated $644K sold.

Truist Financial first reported a position in XLRN in Q4 2019 and held it in 6 quarters. The position peaked at $644K in Q1 2021. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

  • Truist Financial reported no remaining Acceleron Pharma position as of Q2 2021 after selling out during the quarter.
  • Truist Financial sold 4,749 Acceleron Pharma shares in Q2 2021, an estimated $644K.
  • Truist Financial first reported a position in Acceleron Pharma in Q4 2019 and held it in 6 quarters.
  • Truist Financial's Acceleron Pharma position peaked at $644K in Q1 2021.
  • 271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on Truist Financial's 13F filing for Q2 2021, filed 16 Aug 2021.